HIV Drugs Market

Global HIV Drugs Market Share, Research: By Drug Class: Nucleoside Reverse Transcriptase Inhibitors, Multi-Class Combination Drugs, Protease Inhibitors, HIV Integrase Strand Transfer Inhibitors, Others; By Route of Administration; By Drug Type; By End User; By Distribution Channels; Regional Analysis; Supplier Landscape; 2023-2031

Global HIV Drugs Market Outlook

The HIV drug market size attained a value of USD 32.1 billion in 2022. The market is anticipated to grow at a CAGR of 4.5% during the forecast period of 2023-2031 to attain a value of USD 47.8 billion by 2031.

 

Global HIV Drugs Market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

North America accounted for the largest share of the market in 2022. The regional growth can be attributed to the increased number of research and development initiatives for new drug launches, a well-established healthcare system, and the growing adoption of advanced treatment options from HIV infected population. Majority of people with HIV are encountered in low as well as middle-income countries. In 2018, there were 20.6 million people with HIV (57%) in eastern and southern Africa, owing to this, the Middle East and Africa is anticipated to register the highest CAGR over the forecast period.

 

Properties and Applications 

Human Immunodeficiency Virus (HIV) is a virus that causes a chronic and life-threatening disease that can be transferred from one person to another through blood-to-blood and sexual contact. It damages the immune system by destroying CD-4 cells, making the body susceptible to infections and other diseases. The rising prevalence of HIV disease across the world has positively impacted the demand for HIV drugs. These drugs prevent the multiplication of HIV and make the immune system strong enough to resist certain infections, thereby reducing the risk of transmission.

 

HIV Drugs Market By Distribution Channel

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

At present, highly active antiretroviral therapy (HAART) is the most prescribed treatment. It has various combinations of one protease inhibitor and other drugs. These combinations aids in increasing the number of CD4+ cells and decreasing the amount of virus in the blood.

On the basis of drug class, the global HIV drugs market is segmented into:

  • Nucleoside Reverse Transcriptase Inhibitors 
  • Multi-Class Combination Products 
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors 
  • Non-Nucleoside Reverse Transcriptase Inhibitors 
  • Entry Inhibitors — CCR5 Co-Receptor Antagonist 
  • Fusion Inhibitors
  • Others

Based on the distribution channel, the industry can be segregated into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

The EMR report looks into the regional markets in the global HIV drugs market like North America, the Asia Pacific, Europe, Latin America, and the Middle East and Africa.

 

HIV Drugs Market by Region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Market Analysis 

According to the estimates by the World Health Organization (WHO), 37.9 million people are living with HIV, and nearly 2 million people become newly infected at the end of 2018. The growing population density of HIV infected people has been instrumental in the development and introduction of HIV drugs. Besides, the market is also influenced by the rising government initiatives and campaigns to create awareness amongst people regarding the causes, symptoms, and treatments of HIV. Moreover, the introduction of generic drugs acts is another factor that is contributing to the demand for HIV drugs, as they are cost-effective and chemically identical to branded drugs.

Additionally, many international organizations are providing funds to research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions. Owing to the aforementioned factors, the demand for HIV drugs is expected to augment over the forecast period. However, the cost of antiretroviral drugs is relatively high, and patients without healthcare coverage find it extremely difficult to pay, which is likely to restrain the market growth up to some extent, contributing to its negative growth rate. The side effects of these drugs is also preventing the growth of the market with many of the patients giving up the medications due to these harsh side effects, which can include hyperlipidemia, osteopenia, lipodystrophy, and osteoporosis The market is also expected to decline in the forecast period due to the rising awareness about how to prevent the spread of the disease and the upcoming patent expirations.

 

Competitive Landscape 

The report presents a detailed analysis of the following key players in the global HIV drugs market, looking into their capacity, market shares, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Boehringer Ingelheim International GmbH
  • ViiV Healthcare
  • Merck & Co., Inc. 
  • F. Hoffmann-La Roche Ltd. 
  • Gilead Sciences, Inc.
  • Cipla Inc.
  • Johnson & Johnson Services, Inc.
  • Others

The comprehensive report looks into the macro and micro aspects of the industry. The EMR report gives an in-depth insight into the market by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

REPORT FEATURES DETAILS
Base Year 2022
Historical Period 2016-2022
Forecast Period 2023-2031
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Drug Class
  • Route of Administration
  • Drug Type
  • End User
  • Distribution Channels
  • Region
Breakup by Drug Class
  • Nucleoside Reverse Transcriptase Inhibitors
  • Multi-Class Combination Drugs
  • Protease Inhibitors
  • HIV Integrase Strand Transfer Inhibitors
  • Non-Nucleoside Reverse Transcriptase Inhibitors
  • Entry Inhibitors - CCR5 Co-Receptor Antagonist
  • Fusion Inhibitors
  • Others
Breakup by Route of Administration
  • Oral
  • Parenteral
Breakup by Drug Type
  • Branded
  • Generics
Breakup by End User
  • Hospitals
  • Clinics
  • Specialty Centers
  • Research Institutes
  • Others
Breakup by Distribution Channels
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • GSK plc
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sun Pharmaceutical Industries Ltd
  • Mylan N.V.
  • Sanofi
  • Bayer AG
  • ViiV Healthcare group of companies
  • Genentech, Inc
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope
    1.4    Research Methodology
2    Executive Summary
3    HIV/AIDS Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    HIV/AIDS Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America HIV Epidemiology (2016-2031)
    5.3    Europe HIV Epidemiology (2016-2031)
    5.4    Asia-Pacific HIV Epidemiology (2016-2031)
    5.5    Latin America HIV Epidemiology (2016-2031)
    5.6    Middle East & Africa HIV Epidemiology (2016-2031)
6    Global HIV Drugs Market Overview
    6.1    Global HIV Drugs Market Historical Value (2016-2022) 
    6.2    Global HIV Drugs Market Forecast Value (2023-2031)
7    Global HIV Drugs Market Landscape
    7.1    Global HIV Drugs Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Global HIV Drugs Product Landscape
        7.2.1    Analysis by Drug Type
        7.2.2    Analysis by End User
        7.2.3    Analysis by Distribution Channel
8    Cost of Treatment
9    Global HIV Drugs Market Dynamics

    9.1    Market Drivers and Constraints
    9.2    SWOT Analysis
    9.3    Porter’s Five Forces Model 
    9.4    Key Demand Indicators
    9.5    Key Price Indicators
    9.6    Industry Events, Initiatives, and Trends 
    9.7    Value Chain Analysis
10    Global HIV Drugs Market Segmentation
    10.1    Global HIV Drugs Market by Drug Class
        10.1.1    Market Overview
        10.1.2    Nucleoside Reverse Transcriptase Inhibitors
        10.1.3    Multi-Class Combination Drugs
        10.1.4    Protease Inhibitors
        10.1.5    HIV Integrase Strand Transfer Inhibitors
        10.1.6    Non-Nucleoside Reverse Transcriptase Inhibitors
        10.1.7    Entry Inhibitors - CCR5 Co-Receptor Antagonist
        10.1.8    Fusion Inhibitors
        10.1.9    Others
    10.2    Global HIV Drugs Market by Route of Administration
        10.2.1    Market Overview
        10.2.2    Oral
            10.2.2.1    Tablets 
            10.2.2.2    Capsules
        10.2.3    Parenteral
            10.2.3.1    Intravascular
            10.2.3.2    intramuscular
            10.2.3.3    Others
    10.3    Global HIV Drugs Market by Drug Type
        10.3.1    Market Overview
        10.3.2    Branded
        10.3.3    Generics
    10.4    Global HIV Drugs Market by End User
        10.4.1    Market Overview
        10.4.2    Hospitals
        10.4.3    Clinics
        10.4.4    Specialty Centers
        10.4.5    Research Institutes
        10.4.6    Others
    10.5    Global HIV Drugs Market by Distribution Channels
        10.5.1    Market Overview
        10.5.2    Hospitals Pharmacies
        10.5.3    Retail Pharmacies
        10.5.4    Online Pharmacies
        10.5.5    Others
    10.6    Global HIV Drugs Market by Region
        10.6.1    Market Overview
        10.6.2    North America 
        10.6.3    Europe
        10.6.4    Asia Pacific
        10.6.5    Latin America
        10.6.6    Middle East and Africa
11    North America HIV Drugs Market
    11.1    Market Share by Country
    11.2    United States of America
    11.3    Canada
12    Europe HIV Drugs Market
    12.1    Market Share by Country
    12.2    United Kingdom
    12.3    Germany
    12.4    France
    12.5    Italy
    12.6    Others
13    Asia Pacific HIV Drugs Market
    13.1    Market Share by Country
    13.2    China
    13.3    Japan
    13.4    India
    13.5    ASEAN
    13.6    Australia
    13.7    Others
14    Latin America HIV Drugs Market
    14.1    Market Share by Country
    14.2    Brazil
    14.3    Argentina
    14.4    Mexico
    14.5    Others
15    Middle East and Africa HIV Drugs Market
    15.1    Market Share by Country
    15.2    Saudi Arabia
    15.3    United Arab Emirates
    15.4    Nigeria
    15.5    South Africa
    15.6    Others
16    Patent Analysis
    16.1    Analysis by Type of Patent
    16.2    Analysis by Publication year
    16.3    Analysis by Issuing Authority
    16.4    Analysis by Patent Age
    16.5    Analysis by CPC Analysis
    16.6    Analysis by Patent Valuation 
    16.7    Analysis by Key Players
17    Grants Analysis
    17.1    Analysis by Year
    17.2    Analysis by Amount Awarded
    17.3    Analysis by Issuing Authority
    17.4    Analysis by Grant Application
    17.5    Analysis by Funding Institute
    17.6    Analysis by NIH Departments
    17.7    Analysis by Recipient Organization
18    Clinical Trials Analysis 
    18.1     Analysis by Trial Registration Year 
    18.2    Analysis by Trial Status 
    18.3    Analysis by Trial Phase 
    18.4    Analysis by Therapeutic Area 
    18.5    Analysis by Geography  
19    Funding Analysis
    19.1    Analysis by Funding Instances
    19.2    Analysis by Type of Funding
    19.3    Analysis by Funding Amount
    19.4    Analysis by Leading Players
    19.5    Analysis by Leading Investors
    19.6    Analysis by Geography
20    Partnership and Collaborations Analysis
    20.1    Analysis by Partnership Instances
    20.2    Analysis by Type of Partnership
    20.3    Analysis by Leading Players
    20.4    Analysis by Geography
21    Regulatory Framework
    21.1    Regulatory Overview
        21.1.1    US FDA
        21.1.2    EU EMA
        21.1.3    INDIA CDSCO
        21.1.4    JAPAN PMDA
        21.1.5    Others
22    Supplier Landscape
    22.1    F. Hoffmann-La Roche Ltd.
        22.1.1    Financial Analysis
        22.1.2    Product Portfolio
        22.1.3    Demographic Reach and Achievements
        22.1.4    Mergers and Acquisitions
        22.1.5    Certifications
    22.2    Bristol-Myers Squibb Company
        22.2.1    Financial Analysis
        22.2.2    Product Portfolio
        22.2.3    Demographic Reach and Achievements
        22.2.4    Mergers and Acquisitions
        22.2.5    Certifications
    22.3    AstraZeneca
        22.3.1    Financial Analysis
        22.3.2    Product Portfolio
        22.3.3    Demographic Reach and Achievements
        22.3.4    Mergers and Acquisitions
        22.3.5    Certifications
    22.4    GSK plc
        22.4.1    Financial Analysis
        22.4.2    Product Portfolio
        22.4.3    Demographic Reach and Achievements
        22.4.4    Mergers and Acquisitions
        22.4.5    Certifications
    22.5    Merck & Co., Inc.
        22.5.1    Financial Analysis
        22.5.2    Product Portfolio
        22.5.3    Demographic Reach and Achievements
        22.5.4    Mergers and Acquisitions
        22.5.5    Certifications
    22.6    Novartis AG
        22.6.1    Financial Analysis
        22.6.2    Product Portfolio
        22.6.3    Demographic Reach and Achievements
        22.6.4    Mergers and Acquisitions
        22.6.5    Certifications
    22.7    Pfizer Inc.
        22.7.1    Financial Analysis
        22.7.2    Product Portfolio
        22.7.3    Demographic Reach and Achievements
        22.7.4    Mergers and Acquisitions
        22.7.5    Certifications
    22.8    Sun Pharmaceutical Industries Ltd
        22.8.1    Financial Analysis
        22.8.2    Product Portfolio
        22.8.3    Demographic Reach and Achievements
        22.8.4    Mergers and Acquisitions
        22.8.5    Certifications
    22.9    Mylan N.V.
        22.9.1    Financial Analysis
        22.9.2    Product Portfolio
        22.9.3    Demographic Reach and Achievements
        22.9.4    Mergers and Acquisitions
        22.9.5    Certifications
    22.10    Sanofi
        22.10.1    Financial Analysis
        22.10.2    Product Portfolio
        22.10.3    Demographic Reach and Achievements
        22.10.4    Mergers and Acquisitions
        22.10.5    Certifications
    22.11    Bayer AG
        22.11.1    Financial Analysis
        22.11.2    Product Portfolio
        22.11.3    Demographic Reach and Achievements
        22.11.4    Mergers and Acquisitions
        22.11.5    Certifications
    22.12    ViiV Healthcare group of companies
        22.12.1    Financial Analysis
        22.12.2    Product Portfolio
        22.12.3    Demographic Reach and Achievements
        22.12.4    Mergers and Acquisitions
        22.12.5    Certifications
    22.13    Genentech, Inc
        22.13.1    Financial Analysis
        22.13.2    Product Portfolio
        22.13.3    Demographic Reach and Achievements
        22.13.4    Mergers and Acquisitions
        22.13.5    Certifications
23    Global HIV Drugs Market-Distribution Model (Additional Insight)
    23.1    Overview 
    23.2    Potential Distributors 
    23.3    Key Parameters for Distribution Partner Assessment 
24    Key Opinion Leaders (KOL) Insights (Additional Insight)
25    Company Competitiveness Analysis (Additional Insight)

    25.1    Very Small Companies
    25.2    Small Companies
    25.3    Mid-Sized Companies
    25.4    Large Companies
    25.5    Very Large Companies
26    Payment Methods (Additional Insight)
    26.1    Government Funded
    26.2    Private Insurance
    26.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

The global HIV drug market was valued at USD 156.7 billion in 2022.

The market is expected to grow at a CAGR of 4.5% from 2023 to 2031 to reach a value of USD 47.8 billion by 2031.

The market growth is being constrained by the high cost of the treatment and the side effects of the drugs, along with the upcoming threat of patent expirations and the growing awareness about how to effectively curb the spread of the disease.

The key market trend informing the HIV drugs market includes the emerging provision of research institutes funds for R&D activities to develop innovative, affordable, safe, and efficient medicines for effective therapeutic solutions.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific, with North America accounting for the largest share in the market. 

Nucleoside reverse transcriptase inhibitors are the leading drug class of HIV drugs in the industry.

The distribution channel segment is led by hospital pharmacies.  

The major players in the industry are Boehringer Ingelheim International GmbH, ViiV Healthcare, Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Gilead Sciences, Inc., Cipla Inc., and Johnson & Johnson Services, Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $1999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $2999
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 7999     $3999
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 9999     $5999
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER